These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2552315)

  • 41. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients.
    Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR
    Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488
    [No Abstract]   [Full Text] [Related]  

  • 42. Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients.
    Vila A; Guirado LL; Balius A; Díaz M; Baró E; Olaya M; Andrade M; Agraz I; Solá R
    Transplant Proc; 1999 Sep; 31(6):2335-6. PubMed ID: 10500605
    [No Abstract]   [Full Text] [Related]  

  • 43. Acyclovir for cytomegalovirus infection.
    Selby P; Powles R; Stolle K; Stern H
    Br Med J (Clin Res Ed); 1984 Jul; 289(6439):253. PubMed ID: 6331564
    [No Abstract]   [Full Text] [Related]  

  • 44. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients.
    Saliba F; Eyraud D; Samuel D; David MF; Arulnaden JL; Dussaix E; Mathieu D; Bismuth H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1444-5. PubMed ID: 8382876
    [No Abstract]   [Full Text] [Related]  

  • 45. Interferon for prevention of cytomegalovirus reactivation in renal-transplant recipients.
    Himmelstein DU; Woolhandler S
    N Engl J Med; 1983 Nov; 309(19):1193. PubMed ID: 6194436
    [No Abstract]   [Full Text] [Related]  

  • 46. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
    Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
    Fiddian P; Sabin CA; Griffiths PD
    J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
    Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
    [No Abstract]   [Full Text] [Related]  

  • 49. Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis.
    Ahmad T; Simmonds M; McIver AG; McGraw ME
    Pediatr Nephrol; 1994 Aug; 8(4):489-91. PubMed ID: 7947045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients.
    Fletcher CV; Englund JA; Edelman CK; Gross CR; Dunn DL; Balfour HH
    Antimicrob Agents Chemother; 1991 May; 35(5):938-43. PubMed ID: 1649575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Valacyclovir to prevent cytomegalovirus disease after renal transplantation.
    Shapiro ME; Abrams JM
    N Engl J Med; 1999 Sep; 341(12):921. PubMed ID: 10498468
    [No Abstract]   [Full Text] [Related]  

  • 52. Acyclovir prophylaxis for cytomegalovirus in liver transplant recipients.
    Singh N; Yu VL
    J Infect Dis; 1994 Jun; 169(6):1406-7. PubMed ID: 8195627
    [No Abstract]   [Full Text] [Related]  

  • 53. Prophylactic acyclovir in patients receiving bone marrow transplants.
    Trigg ME; Finlay JL; Sondel PM
    N Engl J Med; 1985 Jun; 312(26):1708-9. PubMed ID: 3889644
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of pooled immunoglobulin and acyclovir as prophylaxis against cytomegalovirus disease in recipients of renal allografts.
    Barton IK; Nicholson F
    Nephrol Dial Transplant; 1991; 6(7):525-6. PubMed ID: 1656329
    [No Abstract]   [Full Text] [Related]  

  • 55. Cytomegalovirus vaccination and renal transplantation.
    Glazer JP; Friedman HM; Grossman RA; Barker CF; Starr SE; Plotkin SA
    Lancet; 1978 Jan; 1(8055):90-1. PubMed ID: 74583
    [No Abstract]   [Full Text] [Related]  

  • 56. Cytomegalovirus infection after transplantation: prevention is still the challenge.
    Reusing Junior JO; David-Neto E
    J Bras Nefrol; 2017; 39(4):353-354. PubMed ID: 29319758
    [No Abstract]   [Full Text] [Related]  

  • 57. Prevention of cytomegalovirus disease following renal transplantation.
    Hanshaw JB
    Am J Dis Child; 1977 Aug; 131(8):841-5. PubMed ID: 196502
    [No Abstract]   [Full Text] [Related]  

  • 58. Should renal-transplant patients be screened for C.M.V.?
    Lancet; 1978 Oct; 2(8093):770-1. PubMed ID: 80691
    [No Abstract]   [Full Text] [Related]  

  • 59. Cytomegalovirus disease in renal transplantation.
    Newstead CG
    Nephrol Dial Transplant; 1995; 10 Suppl 1():68-73. PubMed ID: 7617284
    [No Abstract]   [Full Text] [Related]  

  • 60. Antiviral chemoprophylaxis for cytomegalovirus infection.
    Morris DJ
    J Antimicrob Chemother; 1988 Oct; 22(4):569. PubMed ID: 2849602
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.